Mutational analysis of gene families in human cancer

Current Opinion in Genetics and Development

Volumn 15, Issue 1, 2005, Pages 5-12

  Bardelli, Alberto ^a   Velculescu, Victor E ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATASE; PHOSPHOTRANSFERASE;

CANCER; CANCER GENETICS; CATALYSIS; CLINICAL RESEARCH; COLORECTAL CANCER; GENE MUTATION; GENETIC CODE; GENOME; HUMAN; MEDICAL ASSESSMENT; MULTIGENE FAMILY; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; GENOME, HUMAN; HUMAN GENOME PROJECT; HUMANS; MULTIGENE FAMILY; MUTATION; NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHOTRANSFERASES;

EID: 12344313069     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2004.12.009     Document Type: Review

References (46)

1. J. Luo, W.B. Isaacs, J.M. Trent, and D.J. Duggan Looking beyond morphology: cancer gene expression profiling using DNA microarrays Cancer Invest 21 2003 937 949
2. S. Hanash Integrated global profiling of cancer Nat Rev Cancer 4 2004 638 644
3. B. Vogelstein, and K.W. Kinzler Cancer genes and the pathways they control Nat Med 10 2004 789 799
4. R. Simon Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data Br J Cancer 89 2003 1599 1604
5. D.G. Beer, S.L. Kardia, C.C. Huang, T.J. Giordano, A.M. Levin, D.E. Misek, L. Lin, G. Chen, T.G. Gharib, and D.G. Thomas Gene-expression profiles predict survival of patients with lung adenocarcinomas Nat Med 8 2002 816 824
6. X.J. Ma, Z. Wang, P.D. Ryan, S.J. Isakoff, A. Barmettler, A. Fuller, B. Muir, G. Mohapatra, R. Salunga, and J.T. Tuggle A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 5 2004 607 616
7. C. Sawyers Targeted cancer therapy Nature 432 2004 294 297
8. B.J. Druker Imatinib as a paradigm of targeted therapies Adv Cancer Res 91 2004 1 30
9. ••].
10. ••] demonstrate that the clinical success of the EGFR inhibitor gefitinib correlates with activating mutations of EGFR in human tumors. Such results highlight the utility of identifying genetic alterations in signal transducing genes and the development of individualized therapies for patients whose tumors carry such mutations.
11. G.P. Robertson, H.J. Huang, and W.K. Cavenee Identification and validation of tumor suppressor genes Mol Cell Biol Res Commun 2 1999 1 10
12. P.D. Pharoah, A.M. Dunning, B.A. Ponder, and D.F. Easton Association studies for finding cancer-susceptibility genetic variants Nat Rev Cancer 4 2004 850 860
13. H.T. Lynch, and A. de la Chapelle Hereditary colorectal cancer N Engl J Med 348 2003 919 932
14. E.P. Reddy, R.K. Reynolds, E. Santos, and M. Barbacid A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene Nature 300 1982 149 152
15. E. Santos, S.R. Tronick, S.A. Aaronson, S. Pulciani, and M. Barbacid T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes Nature 298 1982 343 347
16. C.J. Tabin, S.M. Bradley, C.I. Bargmann, R.A. Weinberg, A.G. Papageorge, E.M. Scolnick, R. Dhar, D.R. Lowy, and E.H. Chang Mechanism of activation of a human oncogene Nature 300 1982 143 149
17. G.S. Martin The road to Src Oncogene 23 2004 7910 7917
18. P.A. Futreal, L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, N. Rahman, and M.R. Stratton A census of human cancer genes Nat Rev Cancer 4 2004 177 183
19. A. Bardelli, D.W. Parsons, N. Silliman, J. Ptak, S. Szabo, S. Saha, S. Markowitz, J.K. Willson, G. Parmigiani, and K.W. Kinzler Mutational analysis of the tyrosine kinome in colorectal cancers Science 300 2003 949 This study represents the first systematic mutational analysis of any gene family in any human cancer type, identifying novel targets for the individualized analysis and treatment of colorectal tumors.
20. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S.M. Powell, and G.J. Riggins High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554 This manuscript describes the discovery of a high frequency of mutations of the PIK3CA gene in human cancers. These results reveal that PIK3CA is one of the most highly mutated oncogenes identified to date, and suggest that additional such alterations remain to be discovered in cancer genomes.
21. ••] and shows that nearly half of colorectal tumors have alterations in genes that control tyrosine phosphorylation.
22. S.R. Eddy Hidden Markov models Curr Opin Struct Biol 6 1996 361 365
23. A. Bateman, E. Birney, L. Cerruti, R. Durbin, L. Etwiller, S.R. Eddy, S. Griffiths-Jones, K.L. Howe, M. Marshall, and E.L. Sonnhammer The Pfam protein families database Nucleic Acids Res 30 2002 276 280
24. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
25. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 2001 355 365
26. C.L. Corless, J.A. Fletcher, and M.C. Heinrich Biology of gastrointestinal stromal tumors J Clin Oncol 22 2004 3813 3825
27. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, and W. Bottomley Mutations of the BRAF gene in human cancer Nature 417 2002 949 954 The discovery of genetic alterations in BRAF demonstrated that multiple members of a signal transduction pathway can be frequently altered in human cancers.
28. H. Rajagopalan, A. Bardelli, C. Lengauer, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature 418 2002 934
29. J. Downward The ins and outs of signalling Nature 411 2001 759 762
30. A.R. Forrest, T. Ravasi, D. Taylor, T. Huber, D.A. Hume, and S. Grimmond Phosphoregulators: protein kinases and protein phosphatases of mouse Genome Res 13 2003 1443 1454
31. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, A. Osterman, A. Godzik, T. Hunter, J. Dixon, and T. Mustelin Protein tyrosine phosphatases in the human genome Cell 117 2004 699 711
32. M.L. Sulis, and R. Parsons PTEN: from pathology to biology Trends Cell Biol 13 2003 478 483
33. T. Hunter The role of tyrosine phosphorylation in cell growth and disease Harvey Lect 94 1998 81 119
34. N.K. Tonks, and B.G. Neel Combinatorial control of the specificity of protein tyrosine phosphatases Curr Opin Cell Biol 13 2001 182 195
35. B.G. Neel, H. Gu, and L. Pao The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling Trends Biochem Sci 28 2003 284 293
36. J.N. Andersen, P.G. Jansen, S.M. Echwald, O.H. Mortensen, T. Fukada, R. Del Vecchio, N.K. Tonks, and N.P. Moller A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage FASEB J 18 2004 8 30
37. B. Vogelstein, and K.W. Kinzler The multistep nature of cancer Trends Genet 9 1993 138 141
38. T.L. Wang, C. Rago, N. Silliman, J. Ptak, S. Markowitz, J.K. Willson, G. Parmigiani, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Prevalence of somatic alterations in the colorectal cancer cell genome Proc Natl Acad Sci USA 99 2002 3076 3080
39. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, and L. Fulton EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311
40. B.J. Druker, M. Talpaz, D.J. Resta, B. Peng, E. Buchdunger, J.M. Ford, N.B. Lydon, H. Kantarjian, R. Capdeville, and S. Ohno-Jones Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
41. M.G. Kris, R.B. Natale, R.S. Herbst, T.J. Lynch Jr., D. Prager, C.P. Belani, J.H. Schiller, K. Kelly, H. Spiridonidis, and A. Sandler Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial J Am Med Assoc 290 2003 2149 2158
42. M. Huse, and J. Kuriyan The conformational plasticity of protein kinases Cell 109 2002 275 282
43. K.E. Bachman, P. Argani, Y. Samuels, N. Silliman, J. Ptak, S. Szabo, H. Konishi, B. Karakas, B.G. Blair, and C. Lin The PIK3CA gene is mutated with high frequency in human breast cancers Cancer Biol Ther 3 2004 772 775
44. D.K. Broderick, C. Di, T.J. Parrett, Y.R. Samuels, J.M. Cummins, R.E. McLendon, D.W. Fults, V.E. Velculescu, D.D. Bigner, and H. Yan Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas Cancer Res 64 2004 5048 5050
45. I.G. Campbell, S.E. Russell, D.Y. Choong, K.G. Montgomery, M.L. Ciavarella, C.S. Hooi, B.E. Cristiano, R.B. Pearson, and W.A. Phillips Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 64 2004 7678 7681
46. P. Stephens, C. Hunter, G. Bignell, S. Edkins, H. Davies, J. Teague, C. Stevens, S. O'Meara, R. Smith, and A. Parker Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature 431 2004 525 526